Atlanta Braves Holdings, Inc., through its subsidiary, Braves Holdings, LLC, owns and operates the Atlanta Braves Major League Baseball Club in the United States.
FAIL · Does not pass the screen
49.79 USD
Price as of 28 Oct 2026Daily close, not a live quote
Screened 2026-10-28 · the tape above runs as of 16:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price49.79 USD at the 28 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans to puts (put/call 7.06)
Last reviewed28 Oct 2026 (1 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 49.79 against the desk's fair-value range, base estimate 67.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 7.06, read 2026-10-24
Ethical does not pass the values gate
Price49.79 USD
Fair value67.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-20Read Distribution49.41+0.8% to today Accumulation gives way to Distribution with volume flow in agreement
2026-10-13Read Accumulation52.00-4.2% to today Markup gives way to Accumulation
2026-07-02Read Markup50.72-1.8% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Atlanta Braves Holdings, Inc. holds its Distribution at $49.79. Elevated stress, defensive posture warranted, held for 2 days.
As held on the ledger · 2026-10-28
Phase
Distribution · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 2 days
Price at the screen
$49.79
Valuation
N/A trailing · -85.35 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.83
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
51.84%
Below 33%
Interest-bearing debt is 51.8% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
8.26%
Below 49%
Money owed to the company is 8.3% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Atlanta Braves Holdings,'s business is in a permissible area, but its interest-bearing debt is about 52% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BATRK's ethical verdict changes
Today BATRK does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 34.6% margin of safety to the base estimate.
Third-party analyst targets: 5 covering, consensus None. The average target sits +35% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Paying top dollar for a baseball club
Imagine forking out for season tickets when the team is still posting losses and the stadium is only half built. Atlanta Braves Holdings owns the MLB franchise and its mixed-use development site, yet the numbers show revenue growing fast while profits stay negative and returns on equity sit below zero. Our fair value sits well below the current price, which leaves no margin of safety at all.
The forward multiple stretches past three thousand times earnings, a level that prices in perfection the club has not yet delivered. Strong top-line growth from ticket sales and development is real, and the ethical screen is clear, but that does not turn a loss-making business into a bargain when the gap to fair value is this wide.
Analyst targets sit higher, yet the combination of thin margins and unknown competitive edge keeps the opportunity rating at none. Sports assets can swing with performance and local economy alike, so the headline valuation leaves little room for the usual bumps along the way.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BATRK trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Distribution$49.79-0.6%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $60. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Distribution$50.07+0.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $60. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Distribution$50.07+1.3%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $60. Insiders have been net sellers over the past quarter.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $60. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $60. Insiders have been net sellers over the past quarter.
2026-10-02Markup$52.22+4.3%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $60.
2026-08-22Markup$50.06-3.1%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $60.
2026-07-22Markup$51.66+1.9%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $60.
2026-07-18Markup$50.72+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (5 analysts) rates it none, with a mean price target of $60.
2026-07-03Markup$50.72+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
